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Abstract
In this study, we quantitatively investigated the expres-
sion of ß-site amyloid precursor protein cleaving enzyme
(BACE) in the entorhinohippocampal and frontal cortex
of Alzheimer’s disease (AD) and old control subjects. The
semiquantitative estimation indicated that the intensity
of BACE overall immunoreactivity did not differ signifi-
cantly between AD and controls, but that a significantly
stronger staining was observed in the hippocampal re-
gions CA3–4 compared to other regions in both AD
patients and controls. The quantitative estimation con-
firmed that the number of BACE-positive neuronal pro-
files was not significantly decreased in AD. However,
some degeneration of BACE-positive profiles was at-
tested by the colocalization of neurons expressing BACE
and exhibiting neurofibrillary tangles (NFT), as well as by
a decrease in the surface area of BACE-positive profiles.
In addition, BACE immunocytochemical expression was
observed in and around senile plaques (SP), as well as in
reactive astrocytes. BACE-immunoreactive astrocytes
were localized in the vicinity or close to the plaques and
their number was significantly increased in AD entorhi-
nal cortex. The higher amount of ß-amyloid SP and NFT
in AD was not correlated with an increase in BACE immu-
noreactivity. Taken together, these data accent that AD
progression does not require an increased neuronal
BACE protein level, but suggest an active role of BACE in
immunoreactive astrocytes. Moreover, the strong ex-
pression in controls and regions less vulnerable to AD
puts forward the probable existence of alternate BACE
functions.
Copyright © 2005 S. Karger AG, Basel
Introduction
Alzheimer’s disease (AD) is characterized by the extra-
cellular deposition of a 4-kDa peptide of 40–42 aa, the
ß-amyloid peptide (Aß). Aß is deposited into senile
plaques (SP) and the relationship between SP, neurofibril-
lary tangles (NFT) and the pathogenic mechanism of AD
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is controversial. However, several lines of evidence indi-
cate that Aß deposit is involved at an early stage of the
disease. Aß is cleaved from the ubiquitous amyloid pre-
cursor protein (APP), sequentially by two secretases, first
the ß-secretase – producing an ectodomain of APP named
APPsß and the C-terminal 99 amino acids of APP (C99) –
then the Á-secretase, generating the C-terminus of Aß.
Mutations around the ß- and Á-secretase cleavage site in
APP lead to early-onset AD, probably due to an increased
affinity of the secretases for the APP substrate [1].
The enzyme responsible for the main ß-secretase cleav-
age has been identified and cloned. It corresponds to a
membrane-bound aspartyl protease called ß-site APP
cleaving enzyme – BACE1 or BACE – also named Asp2 or
Memapsin2 [2]. Another ß-secretase, BACE2, has been
isolated but the level of BACE2 mRNA is very low or
almost undetectable in human and rat brain while higher
in peripheral tissues [3]. It has been shown that BACE is
the major ß-secretase for generation of Aß in neurons [4]
and would thus represent the key enzyme initiating the
formation of Aß in the brain. However, no mutations or
significant polymorphisms in the sequence of BACE gene
have been found until now in different populations of AD
patients [5–9], although the combination of BACE-spe-
cific allele and ApoE4 may slightly increase the risk of AD
above that of ApoE4 alone [10]. Nevertheless, inhibition
of BACE activity represents an attractive drug target for
AD [11], as knockout mice are healthy despite lacking the
primary ß-secretase activity in the brain [12]. The lack of
Aß generation in the brain of BACE-deficient mice over-
expressing the Swedish APP mutation suggests that the
therapeutic BACE inhibition could reduce Aß in the brain
of AD patients [11].
The few studies on the BACE protein level, BACE
mRNA and BACE enzymatic activity in human AD
patients generally show an increase in BACE protein
expression in the cerebral cortex of AD patients compared
to controls [13, 14], an increase [14] or stable BACE tran-
scription [15, 16], and an increase in BACE enzymatic
activity in various areas and to various degrees [14, 17,
18]. However, only one paper studied the distribution and
localization of BACE by immunocytochemical methods
in the entorhinal cortex (EC) and hippocampus. It reveals
both an increase in the CA1 region and a decrease in the
EC [19].
While BACE inhibition is a promising drug target, its
immunocytochemical expression needs to be further in-
vestigated with quantitative methods. Our study is the
first presenting both a semiquantitative analysis of BACE
immunoreactivity related to the amount of SP and NFT
in the hippocampus, the subiculum (SUB) and the EC,
but also in the frontal cortex (FC), together with a quanti-
tative study of BACE immunopositive profiles.
Materials and Methods
Brain Samples
Brain samples were collected from 12 AD patients, both sporadic
AD and familial AD (FAD) (mean age: 77.5 years), and 16 age-
matched controls (mean age: 72.8 years) without neurological disease
(table 1). Brains were fixed in 10–15% formalin for 4 weeks and
stored in 5% formalin. Tissue blocks were taken from the EC and
from the hippocampal formation including dentate gyrus (DG) and
regions 1–4 of Ammon’s horn (CA1–4), as well as from the frontal
cortex area 9 (FC9) or 10 (FC10) of Brodmann. Not all regions were
available in all cases (table 1). Blocks were embedded in paraffin and
serial 7-Ìm-thick sections were generated. Alternate sections were
used for BACE, Aß and glial fibrillary acidic protein (GFAP) immu-
nocytochemistry, and for the Gallyas silver iodide [20] method to
detect NFT degeneration. Double immunocytochemical staining of
BACE/Aß and of GFAP/Aß was also performed. Finally, a two-step
protocol was used to visualize BACE immunocytochemistry and
Gallyas staining on the same section.
Immunocytochemical Methods
BACE Immunocytochemical Staining
BACE immunocytochemical staining was performed using a
polyclonal goat anti-BACE IgG raised against the human BACE1-
specific amino acid sequence 485–501 (Chemicon International Inc.
AB5488, dilution 1:2,500; no similarity to BACE2). A biotinylated
rabbit antigoat (Dako Diagnostics AG E0466, dilution 1:300) was
used as secondary antibody. The specificity of the BACE antibody is
guarantied by the firm for formalin-fixed paraffin-embedded sec-
tions and has been demonstrated both with Western blots and immu-
nocytochemistry [21]. Immunocytochemistry also employed an avi-
din-biotin-peroxidase complex kit (ABC kit; Dako K0355; solutions
A and B, dilution 1%) and normal rabbit serum (Dako X0902, dilu-
tion 1:10). Phosphate-buffered saline (PBS; 0.01 M and 0.1 M, pH
7.4) was used for rinsing and for dilution of 3,3)-diaminobenzidine
(DAB; Sigma Aldrich Chemie D5637), which was employed for anti-
body revelation. PBSA (1% of albumin from bovine serum in PBS,
0.01 M, pH 7.4) was used for antibodies and ABC kit dilution.
Deparaffinized sections were permeabilized with 0.1% Triton
X-100 in PBS 0.1 M for 15 min, rinsed 3 times in PBS 0.1 M. To
reduce background, they were pretreated in 10% methanol and 0.3%
H2O2 (30%) in PBS 0.1 M for 15 min and rinsed twice in water. To
enhance immunocytochemical staining, they were put in buffered
citric acid (0.01 M; pH 6.0) in the microwave (800 W) for 5 min.
After rinsing twice in PBS 0.01 M (2 ! 2.5 min) and incubating for
10 min in normal rabbit serum (dilution 1:10), incubation with the
first antibody (dilution 1:2,500) was carried out overnight at 4°C.
After rinsing in PBS 0.01 M (2 ! 5 min), sections were incubated
with the secondary antibody (dilution 1:300) for 1 h at room temper-
ature. Sections were rinsed twice in PBS 0.01 M and incubated in a
solution of ABC kit for 35 min at room temperature. After rinsing
twice in PBS 0.01 M, staining was revealed for 10 min in 0.03% DAB
and 0.015% H2O2 in PBS 0.01 M. Sections were rinsed twice in tap
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Table 1. Description of cases and
availability of material Case Sex Age PMD, h Group Cause of death Region
1 M 30 12 C myocardial infarct FC10
2 M 48 10 C myocardial infarct Hipp/FC10
3 M 52 16 C myocardial infarct FC10
4 M 55 19 C cardiac failure FC10
5 M 71 38 C pancreatic carcinoma FC10
6 F 71 11 C cardiac insufficiency FC10
7 F 77 19 C pulmonary embolism Hipp
8 M 78 22 C urinary bladder carcinoma Hipp/FC9
9 M 78 28 C bronchopneumonia Hipp/FC9
10 M 78 24 C thrombosis FC10
11 M 84 !24 C cachexia FC10
12 F 84 30 C myocardial infarct Hipp/FC9
13 F 87 92 C uterus carcinoma Hipp
14 M 89 15 C bronchopneumonia FC9
15 F 90 61 C myocardial infarct Hipp
16 M 93 18 C infection FC10
17 M 55 18 FAD coma FC10
18 M 67 1 AD bronchopneumonia FC10
19 M 69 9 FAD cardiac failure Hipp/FC10
20 M 71 20 FAD breathing failure Hipp/FC10
21 M 71 20 AD cachexia FC10
22 F 80 21 AD renal insufficiency Hipp/FC9
23 F 80 – AD – FC10
24 M 81 28 AD bronchoaspiration FC10
25 M 86 23 AD bronchopneumonia FC10
26 F 87 64 AD cardiac insufficiency Hipp/FC9
27 F 88 7 AD cardiac insufficiency Hipp/FC9
28 F 95 16 AD myocardial infarct Hipp/FC9
M = Male; F = female; C = control case; AD = Alzheimer’s disease; FAD = familial Alzhei-
mer’s disease; PMD = postmortem delay; Hipp = hippocampal region including EC and SUB;
FC9 = frontal area 9; FC10 = frontal area 10.
water, twice in water and counterstained with Mayer hematoxylin
without citric acid for 1 min, then rinsed tree times in tap water and
counterstained in a Scott blue solution for 30 s. Sections were dehy-
drated and mounted with Pertex. For each batch of sections, control
consisted of omitting primary antibody.
Aß and GFAP Immunocytochemical Staining
Aß immunocytochemical staining was performed using a mono-
clonal mouse anti-Aß IgG raised against the human sequence 8–17 of
the Aß protein (Dako M0872, dilution 1:100) and a biotinylated rab-
bit antimouse (Dako E0413, dilution 1:300) as secondary antibody.
Immunocytochemical staining of GFAP (principal intermediate fila-
ment of astrocytes) was detected using a polyclonal rabbit antihuman
GFAP (Dako Z0334, dilution 1:1,500) and a biotinylated swine anti-
rabbit immunoglobulin (Dako E0353, dilution 1:300) as secondary
antibody. All sections were pretreated in methanol: H2O2 (97:3) for
10 min to reduce background, rinsed twice in water and only Aß sec-
tions were put in 80% formic acid for 5 min to enhance immunocyto-
chemical staining. After rinsing twice in water and twice in PBS
0.01 M, sections were incubated for 10 min in normal rabbit serum
(Aß) or normal swine serum 1:10 (GFAP) and then with primary
antibody over night at 4°C. After rinsing in PBS 0.01 M (2 ! 5 min),
sections were incubated with the secondary antibody for 1 h at room
temperature. Revelation, counterstaining and control were per-
formed as above.
BACE/Aß and GFAP/Aß Double Immunocytochemical Staining
To reveal BACE, a peroxidase substrate (Novared kit, Vector
Laboratories, Inc. SK-4800) was used. Then a nickel method was
used to reveal the Aß labeling, employing a solution of Tris buffer
(0.1 M; pH 7.4) made of 0.016 M Trizma base and of 0.084 M Triz-
ma-HCl in water, solution A made of 0.2% (NH4)2Ni(SO4)2 ! 6H2O
in Tris buffer, solution B made of 0.2% (NH4)2Ni(SO4)2 with 0.035%
DAB in Tris buffer and solution C made of solution B plus 0.01%
H2O2 (30%). Pretreatment was identical to pretreatment of the
BACE method except for the citric acid bath replaced by the formic
acid bath (due to the combination with Aß immunocytochemical
staining; see above) for 5 min at room temperature. To perform the
first immunocytochemical staining, sections were incubated in nor-
mal rabbit serum (see above), then with the primary anti-BACE anti-
body at 4°C overnight, rinsed in PBS 0.01 M (2 ! 5 min) and incu-
bated with the secondary antibody (dilution 1:300) for 1 h at room
temperature. Sections were rinsed twice in PBS 0.01 M and incu-
bated in a solution of the ABC kit for 35 min at room temperature.
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After rinsing twice in PBS 0.01 M, sections were revealed using the
peroxidase substrate Novared kit for 10 min. To perform the second-
ary staining, sections were rinsed twice in tap water, twice in water,
twice in PBS 0.01 M and incubated in normal rabbit serum for
10 min (see above). Sections were incubated at 4°C overnight with
the primary anti-Aß antibody (dilution 1:100), rinsed in PBS 0.01 M
(2 ! 5 min) and incubated with the secondary anti-Aß antibody (di-
lution 1:300) for 1 h at room temperature. After rinsing twice in PBS
0.01 M, sections were incubated in an ABC kit for 35 min at room
temperature. Sections were rinsed twice in PBS 0.01 M and the per-
oxidase was revealed by conditioning in Tris buffer (twice) for
10 min, in solution A for 10 min, in solution B for 10 min and in
solution C for 10 min. Counterstaining was performed as above.
GFAP/Aß double immunocytochemical staining was identical to
BACE/Aß double immunocytochemical staining. GFAP was labeled
first (antibody’s dilution 1:2,500), revealed with the Novared kit and
Aß was labeled afterwards (antibody’s dilution 1:100), revealed using
the nickel method.
BACE/Gallyas Two-Step Protocol
BACE immunocytochemistry was performed first as described
for BACE simple immunocytochemical staining and photographs
were taken at specific locations on humid unmounted sections; modi-
fied Gallyas silver iodide staining [20] with light green SF (Chroma-
Gesellschaft no 1B211) counterstaining was performed on the same
section and photographs were taken at the same locations, allowing
detection of possible signal colocalization.
Semiquantitative Study and Statistical Analysis
BACE immunopositive neurons, Aß SP, NFT and mature GFAP-
positive astrocytes were estimated semiquantitatively under bright-
field illumination using a Zeiss Axioplan microscope, at a magnifica-
tion of !200, in all sampled regions, i.e. in all layers of EC, FC9 and
FC10, as well as in DG, CA3–4 and CA1 regions of the hippocampus
and in the SUB. The screening was performed by 2 independent peo-
ple using at least 12 fields on 2–3 different sections in each region and
in each brain. In addition, each observer performed screenings twice
in order to check his own observations. Estimations were compara-
ble, taking into account both the amount of stained elements and the
intensity of the staining. Tables 3 and 4 indicate that they varied
from 0 (no staining) to + (weak staining), ++ (medium staining), +++
(strong staining) and ++++ (very strong staining). For data analysis,
these semiquantitative estimations were graded from 0 to 4 (fig. 2).
We have recently used this method to quantify LMO4 protein immu-
noexpression in Alzheimer brains [22].
Data were analyzed with the help of a statistical analysis package
SAS [23]. Explanatory data analysis included a box-plot representa-
tion of the estimations of BACE immunocytochemical staining, Aß-
stained SP, Gallyas-marked NFT and GFAP-reactive astrocytes
(fig. 2). A nonparametric test such as Kruskal-Wallis variance analy-
sis was used to compare groups and a Spearman correlation analysis
was performed between parameters.
Quantitative Study and Statistical Analysis
In addition to the semiquantitative analysis, BACE immunoposi-
tive profiles were quantified with an image analysis system in a col-
umn of cortex from the EC and from the FC10.
Morphometry was performed using a Zeiss/Kontron image analy-
sis system. This system has a stage with stepping motors for the 3 axes
and a video camera for image capture (512 ! 512 pixels). The histo-
logical section can be moved under program control in order to scan
the whole cortical depth along columns going perpendicularly from
pia to white matter. For the best acuity, each individual field was
viewed at a magnification of !125 for EC, which made the counting
window 448 Ìm wide and 324 Ìm high, and at a magnification of
!250 for FC, which made the counting window 227 Ìm wide and
163 Ìm high. Three cortical columns were screened in EC and FC10,
depending on the available material (table 1). We quantified the
number of BACE well-marked neuronal profiles, corresponding to
complete cells in the section, using a semiautomatic threshold proce-
dure, based on the optical density of neuronal profiles. The optical
density corresponded to the intensity of the transmitted light and was
measured on a scale going from 0 (100% transmitted light) to 255
(0% transmitted light) for each pixel. The profile segmentation was
performed in an interactive way, including the possibility of visual
correction by the user (elimination of artifacts or separation of fused
profiles). Criteria of object inclusion were the shape and the size of
the neuronal perikarya, as well as a strong immunoreactive status.
Parameters such as the position of the neuronal profile in the column
and the neuronal surface area were measured by means of our specif-
ically designed software. In parallel, we quantified the number of
BACE-immunonegative neurons – including very weakly marked
neurons – as well as the number of BACE-immunopositive typical
reactive astrocytes. Knowing the surface of the cortical column, we
calculated the number of cellular profiles per square millimeter of
cortex (densities), in 7-Ìm-thick sections (table 4). Indeed, the num-
ber of profiles reflects the number of neurons in sections of similar
thickness treated with similar procedures. Data were analyzed with
the help of the statistical analysis package [23]. As the distributions of
densities or surface areas of neuronal profiles did not always fulfill
criteria for normality, differences in the densities of neuronal profiles
between AD and controls were analyzed with a Kruskal-Wallis non-
parametric test and the distribution of surface areas with a ¯ 2 test.
Results
BACE Protein Immunoreactivity in Control and AD
Brains 
BACE immunostaining was present in the control
brains in all regions examined (fig. 1A–F). It was mainly
specific for the neuronal cell bodies and did not mark glial
or endothelial cells except in some localizations, where
reactive astrocytes with fibrillary prolongations could be
observed. The neuronal staining appeared intracytoplas-
mic, making a ring around the nucleus and often at the
basis of the dendrites, which was clearly shown by the
blue counterstaining of the nucleus. In the SUB and in the
EC, most neurons were marked, but the staining was par-
ticularly strong in EC layers 2 and 5. In the hippocampus,
all subdivisions were marked including the DG, but the
region CA3–4 exhibited the strongest staining, followed
by the region CA1. In the FC, BACE staining was present
in both available areas 9 and 10 and the intensity was
qualitatively similar to that in other regions. Semiquanti-
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Fig. 1. Photomicrographs of 7-Ìm paraffin sections showing BACE
immunocytochemical staining with anti-BACE (Chemicon AB5488,
dilution 1:2,500) in 6 different regions of control brains. Counter-
staining with Mayer hematoxylin and Scott blue. A Case No. 15
(table 1): DG. B Case No. 8: CA3–4. C Case No. 13: CA1. D Case
No. 12: SUB. E Case No. 8: layer 2 of EC. F Case No. 8: layer 5 of FC;
inserts show magnification of one neuron in each case (asterisk).
Immunocytochemical staining – clearly cytoplasmic – is the stron-
gest in the region CA3–4 (see also fig. 2). Scale: 50 Ìm; insert:
25 Ìm.
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Table 2. Semiquantitative estimation of BACE immunostaining in the entorhinohippocampal region
Case Sex Age Group DG
BACE SP NFT GFAP
CA3–4
BACE SP NFT GFAP
CA1
BACE SP NFT GFAP
SUB
BACE SP NFT GFAP
EC
BACE SP NFT GFAP
2 M 48 C ++ 0 0 0 ++++ 0 0 ++ +++ 0 0 0 +++ 0 0 0 +++ 0 0 0
7 F 77 C + 0 0 0 +++ 0 0 ++ ++ 0 0 0 + 0 0 0 +++ 0 0 0
8 M 78 C ++ 0 0 0 ++++ 0 0 ++++ ++ 0 0 0 ++ 0 0 0 ++ 0 0 0
9 M 78 C ++ 0 0 0 +++ 0 0 ++++ 0 0 0 + 0 0 0 0 ++ 0 + ++
12 F 84 C ++ 0 0 0 ++++ 0 0 ++++ +++ 0 + 0 ++ 0 + 0 ++ + +++ +
13 F 87 C ++ 0 0 0 +++ 0 0 +++ +++ 0 0 0 +++ 0 0 0 +++ 0 ++ 0
15 F 90 C ++ 0 0 0 ++++ 0 0 +++ ++++ 0 0 0 ++ 0 0 0 +++ 0 + 0
19 M 69 FAD ++ + 0 0 ++++ ++ + +++ ++ ++ ++ 0 ++ 0 ++++ ++ ++ + +++ ++
20 M 71 FAD 0 0 0 0 + ++ ++ ++++ ++ 0 + ++++ + ++ +++ ++++ 0 ++ +++ ++++
22 F 80 AD ++ 0 0 0 ++++ 0 + ++++ +++ + +++ 0 ++ 0 ++++ + ++ ++ +++ ++
26 F 87 AD ++ 0 0 0 +++ 0 0 ++++ ++ 0 ++ ++ ++ 0 ++++ +++ ++ ++ ++ ++
27 F 88 AD + 0 0 0 +++ + 0 +++ +++ + 0 0 +++ ++ ++ 0 ++ +++ ++ +
28 F 95 AD + 0 0 0 ++++ 0 0 +++ ++ + ++ ++ ++ ++ ++++ ++ ++ +++ ++ ++
M = Male; F = female; C = control case; BACE = immunostaining with the polyclonal antibody goat anti-BACE; SP = senile plaques immunostained with the monoclonal
antibody mouse anti-Aß; NFT = neurofibrillary tangles stained with the Gallyas method; GFAP = immunostaining with the polyclonal antibody rabbit antihuman glial
fibrillary acidic protein. Semiquantitative estimation data, taking into account both the intensity of staining and the number of stained elements, were graded as 0 = no staining;
+ = weak; ++ = medium; +++ = strong; ++++ = very strong.
tative data from areas 9 and 10 were pooled (table 3;
fig. 2)
The overall staining estimation, taking into account
both the staining intensity and the number of stained ele-
ments, was not markedly different in control cases from
different ages (tables 2, 3), meaning that aging alone does
not affect the amount of intraneuronal BACE expression
in the studied regions. Similarly, the semiquantitative
estimation of BACE immunostaining revealed no marked
differences between AD and control brains in any of the
regions (tables 2, 3). Kruskal-Wallis analysis confirmed
that there were no statistically significant differences be-
tween control and AD brains. In both controls and AD
patients, greater BACE expression was found in the region
CA3–4 compared to other regions (controls: p = 0.001;
AD patients: p = 0.03). Thus, the global neuronal BACE
expression did not change in AD, with, however, a trend
to lower values for EC, where the probability (p = 0.056)
was just at the limit of significance.
BACE Protein Immunoreactivity in Relation to SP
and NFT 
We observed – rarely in old controls, mainly in AD
entorhinohippocampal regions – BACE expression in the
SP as well as in reactive astrocytes (fig. 3A–C). Using ei-
ther simple staining with the anti-BACE antibody
(fig. 3A) or double staining with both anti-BACE and anti-
Aß antibodies (fig. 3B), we could observe that BACE
expression was localized in the periphery of the plaque,
while the center was strongly positive for Aß. There were
two different types of SP, with the periphery showing ei-
ther diffuse BACE reactivity or intermingled Aß and
BACE reactivity. In addition, reactive BACE-positive
astrocytes were also observed at the border of the plaque
(fig. 3B). When using a GFAP antibody, similar features
were observed, with strong GFAP staining at the periph-
ery of many SP and GFAP-positive astrocytes at the bor-
der of SP (fig. 3C).
SP stained with anti-Aß and NFT marked with Gallyas
were estimated semiquantitatively on sections adjacent to
BACE staining estimation (tables 2, 3; fig. 2). Kruskal-
Wallis analysis indicated that the increase in SP estima-
tion in AD compared to control cases was statistically sig-
nificant in all regions except in DG (EC: p = 0.003; SUB:
p = 0.001; CA1: p = 0.001; CA3–4: p = 0.004; FC: p !
0.001). The amount of NFT was also increased in a statis-
tically significant way in all AD regions except in DG (EC:
p = 0.02; SUB: p = 0.002; CA1: p = 0.005; CA3–4: p =
0.001; FC: p ! 0.001). In addition, taking into account
anatomical landmarks such as capillaries on two adjacent
sections permitted to detect that BACE immunostaining
and NFT degeneration often concerned similar neuronal
populations. In several entorhinohippocampal localiza-
tions, but mainly in the SUB, neurons expressing BACE
immunocytochemistry were also marked for NFT degen-
eration. Further, using a two-step procedure for double-
labeling on the same section (see Materials and Methods)
ascertained that they were exactly the same neurons
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Fig. 2. Box-plot representation of BACE + profiles, Aß + SP, NFT and
GFAP + reactive astrocytes estimations. For data analysis, semiquan-
titative estimation data from tables 2 and 3, taking into account both
the intensity of staining and the number of stained elements, were
graded from 0 (no staining) to 4 (++++ = very strong staining). Within
the box-plot, the box itself represents the interquartile range (inferior
quartile range = 25%; superior quartile range = 75%), the horizontal
line, the median value and the cross, the mean; the vertical lines
(whiskers) indicate values laying outside the box within a range of
!1.5 that of interquartiles and the square symbol represents values
out of the whisker range. There are no significant differences between
control (C) and AD cases for BACE + profiles in any of the regions,
while significant differences are observed in all regions except DG for
SP and NFT. Differences for GFAP + reactive astrocytes are signifi-
cant in all regions except DG and CA3–4. Between regions, the differ-
ence in BACE expression is significant only for CA3–4 versus others in
both AD and controls. For probabilities, see text.
Table 3. Semiquantitative estimation of BACE immunostaining in
the FC (areas 9 and 10)
Case Sex Age Group BACE SP NFT GFAP
1 M 30 C + 0 0 0
2 M 48 C ++ 0 0 0
3 M 52 C ++ 0 0 0
4 M 55 C + 0 0 0
5 M 71 C ++ 0 0 +
6 F 71 C ++ 0 0 0
8 M 78 C + 0 0 0
9 M 78 C +++ 0 0 +
10 M 78 C ++ 0 0 +
11 M 84 C ++ 0 0 0
12 F 84 C + 0 0 0
14 M 89 C + 0 0 0
16 M 93 C ++ 0 0 +
17 M 55 FAD + ++ ++++ ++++
18 M 67 AD +++ ++ + +
19 M 69 FAD + ++ 0 +++
20 M 71 FAD + ++ 0 +++
21 M 71 AD ++ ++ +++ ++
22 F 80 AD ++ +++ + ++
23 F 80 AD + +++ +++ +++
24 M 81 AD ++ ++ + +
25 M 86 AD ++ ++ + ++
26 F 87 AD +++ ++ ++ +
27 F 88 AD +++ +++ 0 0
28 F 95 AD ++ +++ 0 ++
M= Male; F = female; C = control case; BACE = immunostaining
with the polyclonal antibody goat anti-BACE; SP = senile plaques
immunostained with the monoclonal antibody mouse anti-Aß;
NFT = neurofibrillary tangles stained with the Gallyas method;
GFAP = immunostaining with the polyclonal antibody rabbit anti-
human glial fibrillary acidic protein. Semiquantitative estimation
data, taking into account both the intensity of staining and the num-
ber of stained elements, were graded as 0 = no staining; + = weak;
++ = medium; +++ = strong; ++++ = very strong.
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
13
0.
60
.4
7.
22
 - 
7/
7/
20
16
 2
:1
7:
44
 P
M
178 Dement Geriatr Cogn Disord 2005;19:171–183 Leuba/Wernli/Vernay/Kraftsik/Mohajeri/
Saini
3
4
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
13
0.
60
.4
7.
22
 - 
7/
7/
20
16
 2
:1
7:
44
 P
M
BACE Expression in Alzheimer’s Disease Dement Geriatr Cogn Disord 2005;19:171–183 179
Table 4. Mean (B SD) number of cellular
profiles per square millimeter of cortex in
7-Ìm sections
Neurons
BACE+
Neurons
BACE–
Total
neurons
Astrocytes
BACE+
Entorhinal cortex C 98.4B27.4 38.4B9.8 136.9B35.7 9.9B4.7
AD 82.5B10.1 16.3B17.7 98.7B25.0 74.7B112.6
Frontal cortex (area 10) C 182.2B37.6 81.8B20.1 264.0B47.4 7.1B6.2
AD 188.5B51.7 104.2B50.0 292.8B83.4 9.8B8.0
C = Control cases. In the EC, the difference between AD patients and controls is statisti-
cally significant only for the number of BACE-negative neuronal profiles (p = 0.037) and for
the number of BACE-positive astrocytes (p = 0.005). In the FC, there are no significant dif-
ferences.
(fig. 4A–D). Thus, neurons expressing BACE do degener-
ate in the course of AD, or in other words, degenerating
neurons still express intracytoplasmic BACE. Finally, re-
garding the semiquantitative estimation of GFAP stain-
ing, Kruskal-Wallis analysis indicated that in all regions
except DG and CA3–4, GFAP expression was significant-
ly higher in AD patients than in controls (EC: p = 0.007;
SUB: p = 0.003; CA1: p = 0.041; FC: p = 0.001).
We tested the possible correlation between BACE im-
munostaining and the degree of NFT degeneration or SP
deposition in pooled aged controls and AD patients, using
a nonparametric Spearman correlation. No significant
positive correlation was found between neuronal BACE
Fig. 3. Photomicrographs of 7-Ìm paraffin sections showing SP in
one 84-year-old control (case 12, EC, layer 2; table 1). A SP is marked
with anti-BACE antibody revealed with DAB; the center is not
marked. B SP is marked with anti-BACE antibody revealed with
Novared, combined with anti-Aß revealed with the nickel method;
the center is obviously Aß positive, while the periphery indicates
both BACE and Aß positivity; in addition, an astrocyte is clearly
BACE positive. C SP marked with anti-GFAP antibody revealed
with Novared, combined with anti-Aß revealed with the nickel meth-
od; again the center is obviously Aß positive, while the periphery
indicates GFAP staining and a reactive positive astrocyte. All sec-
tions were counterstained with hematoxylin and Scott blue. Scale =
50 Ìm.
Fig. 4. Photomicrographs of 7-Ìm paraffin sections showing BACE
staining in NFT following a two-step protocol. A, C SUB marked
with anti-BACE antibody revealed with DAB in case 22 (table 1).
B, D SUB stained with Gallyas and light green counterstaining on the
same section. A, B Scale: 100 Ìm. C, D Scale: 25 Ìm. Neurons
marked with an arrow or asterisk demonstrate clearly that BACE
staining is present together with NFT degeneration; the neuron with
an asterisk is enlarged in C and D and shows that BACE immunocy-
tochemical staining seems to parallel NFT degeneration fibrils.
expression and the amount of amyloid SP, NFT or GFAP
staining. A significant positive correlation between the
amount of SP and NFT degeneration was found in all
regions except DG (EC: R = 0.63, p = 0.021; SUB: R =
0.079, p = 0.001; CA1: R = 0.77, p = 0.002; CA3–4: R =
0.89, p ! 0.001; FC: R = 0.81, p ! 0.001).
Quantitative Analysis 
For quantitative analysis, only EC and FC10 have
been taken into account. The number of BACE-positive
(strong staining) and BACE-negative (no or very weak
staining) neuronal profiles were calculated per square mil-
limeter (see Materials and Methods) and similar data
were obtained for BACE-positive reactive astrocytes (ta-
ble 4). Variations between controls and AD patients were
analyzed with a Kruskal-Wallis test. In EC, we observed
lower neuronal values in AD patients compared to con-
trols. However, the difference was statistically significant
only for BACE-negative neuronal profiles (p = 0.037), not
for BACE-positive neuronal profiles. The total number of
profiles was decreased, but the difference was at the limit
of significance (p = 0.057). In FC, the densities of BACE-
positive, BACE-negative and total neuronal profiles were
almost similar and differences were not statistically signifi-
cant. An interesting feature was the presence of a very high
number of BACE-positive reactive astrocytes in EC of AD
cases, about 7 times more than in controls (p = 0.005), but
this was not the case in FC10 (see Discussion). Densities
for BACE-positive profiles were also analyzed separately at
three different cortical levels corresponding roughly to
superficial, medium and deep layers, but Kruskal-Wallis
analysis indicated no significant difference between AD
patients and controls in the different layers (data not
shown). However, there was a significant difference in the
surface area frequency distribution of BACE-positive neu-
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ronal profiles between AD and control cases. A ¯ 2 test dem-
onstrated more small neuronal profiles than expected in
AD compared to controls in the superficial, medium and
deep layers of both EC and FC10 (p ! 0.001).
Discussion
Our data have shown that the immunoexpression of
the ß-secretase enzyme, BACE, is not increased in vulner-
able brain neurons of the entorhinohippocampal regions
of AD brains, or in pyramidal neurons of the FC. In addi-
tion, BACE expression is strong in CA3–4 pyramidal neu-
rons and present to a lesser degree in granular neurons of
the DG, less vulnerable to the neurodegeneration process.
Our semiquantitative analysis indicated that in all regions
examined, the level of expression was similar for control
and AD cases, while the only statistically significant dif-
ference was between regions, with a higher BACE expres-
sion in CA3–4 for both control and AD groups. However,
data in the EC reached the limit of significance and we
performed a quantitative analysis of BACE-positive neu-
ronal profiles in EC compared to FC10. Although the esti-
mated mean number of neuronal BACE-positive profiles
per square millimeter of cortex was lower in EC of AD
cases compared to controls, the results were not statisti-
cally significant and confirmed the semiquantitative anal-
ysis. As the mean values for BACE-negative and total
numbers of profiles were also decreased, this phenome-
non is probably due to neuronal loss, which has been
clearly demonstrated in AD EC [24]. Degeneration of
BACE neuronal profiles was further attested in our data,
by their smaller surface area in AD compared to controls
and by the localization of BACE in NFT degenerating
neurons marked by Gallyas argentation. Another study
established that the density of BACE immunoreactivity
was significantly decreased in EC of AD cases, while it
was not changed in CA4 and SUB, and increased only in
CA1 [19], partially in agreement with our estimations.
But to our knowledge, our study is the first showing
unchanged numbers of BACE neuronal profiles per
square millimeter of cortex in EC and FC. Quantification
of BACE mRNA showed no significant change in hippo-
campal sections of AD brains [15, 16], suggesting an
equally stable level of protein, although a recent paper
indicated some increase [14]. Other studies showed in-
creased BACE expression in AD cerebral cortex by West-
ern blots [13, 14] and/or increased BACE enzymatic
activity in the temporal cortex or other regions [14, 17,
18], as well as in normal aging of several species [25].
However, these studies do not distinguish between neu-
ronal BACE profiles and BACE expression in and around
SP or in reactive astrocytes. While the EC begins to loose
neurons in early AD [24], the temporal cortex appears
damaged with progressing AD [26]. Therefore, a raise in
BACE enzymatic activity may be explained by increased
activity in surviving neurons, or by a glial upregulation,
which has not been studied by the authors [17]. In our
data, the number of BACE-positive reactive astrocytes in
EC has been found highly increased in AD, thus influenc-
ing the overall immunoreactivity.
Altered processing of APP is considered a key event in
the pathological cascade of AD and BACE is critical in Aß
biosynthesis, leading to amyloid deposits and SP. BACE
has been shown in almost all cellular compartments where
APP is found [27], with a maximal activity located within
the lumen of acidic intracellular compartments [11]. This
may favor the catalytic activity required for Aß formation
and suggests a positive correlation between the enzymatic
expression of BACE and Aß deposit [14, 25]. We observed
no positive correlation between the immunocytochemical
expression of BACE and Aß deposit in our cases, but this
does not contradict a possible raise in enzymatic activity.
Other authors have shown that if BACE activity increased
with age, the BACE protein level was unchanged [25].
Interestingly, among the examined structures, the CA3–4
subdivision of the hippocampus has the strongest BACE
expression and shows little or no SP and NFT, in spite of
many reactive astrocytes. This implies the existence of
other functions for BACE than APP processing in hu-
mans, in agreement with observations showing that
BACE had probably other physiological substrates in cell
lines [28]. In FC pyramidal neurons, BACE is also
present, without concomitant severe degeneration. Simi-
lar BACE staining in intact brain regions was reported by
the authors cited above, questioning the role of BACE in
healthy neurons.
Altogether, our results suggest that the BACE neuronal
level is not the limiting factor in the pathological cascade
leading to Aß deposit in humans. This appears similar in
mice, where no differences in BACE expression were
observed between normal and transgenic lines overex-
pressing APP [29–32]. On the other hand, transgenic mice
expressing human BACE showed increased amyloidogen-
ic processing of APP, as demonstrated by increased levels
of Aß40 and Aß42, suggesting that the rate-limiting cleav-
age in the generation of Aß was regulated by BACE [32].
Besides, BACE knockout mice have been healthy [12] and
BACE knockout mice overexpressing Swedish APP had
no Aß in the brain, leading to the proposal of a therapeutic
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BACE inhibition, aimed to reduce Aß in the brain of AD
patients [11]. Recently, double transgenic mice, BACE
knockout and overexpressing human APP, showed be-
havioral and electrophysiological rescue correlated with a
dramatic decrease in Aß deposit [33], further validating
BACE inhibition as a therapeutic target. As normal astro-
cytes exhibit little ß-secretase activity [11], the presence
of BACE in reactive AD astrocytes – also marked by
GFAP – constitutes an intriguing phenomenon, already
observed in aged APP transgenic mice [31, 34, 35]. In
double transgenic mice, overexpressing both BACE and
its substrate APP, BACE-reactive astrocytes were associ-
ated with an accelerated amyloid plaque formation [35].
In our data, positive astrocytes were often in the vicinity
of Aß SP, mainly in the entorhinohippocampal region,
suggesting a direct link between SP formation and induc-
tion of BACE expression in reactive astrocytes in human.
Indeed, under chronic but not acute experimental stress,
astrocytes, contrarily to microglial cells, appear to express
BACE, which simulates Alzheimer long-term degenera-
tion [34]. A critical step in neurodegeneration seems to be
reached when pathological glial activation includes astro-
cytes in addition to microglia [36]: differentiated reactive
astrocytes no longer appear to be able to control micro-
glial nitric oxide production, leading to the production of
neurotoxic peroxynitrates, or to maintain extracellular
ion homeostase, favoring excitotoxicity. The whole neu-
ronal microenvironment may be troubled, contributing to
oxidative stress, the latter being able in turn to increase
BACE neuronal production or activity [37].
Finally, the exact mechanism leading to neurodegener-
ation in sporadic AD is still unknown. Within the domi-
nant conceptual framework of the Aß cascade, one should
certainly reconsider the competition between ß-secretase
amyloidogenic and ·-secretase nonamyloidogenic cleav-
age [38]. A pathway involving sumoylation regulating ·-
mediated versus ß-mediated cleavage of APP has been
described [39] and puts emphasis on targeting the stimu-
lation of ·-secretase as a possible drug to reduce Aß. So
far, the expression of ·-secretase has not been considered
predominant in the cascade. But a decrease in ·-secretase
activity has been shown in the temporal cortex of AD
patients without concomitant decrease in immunocyto-
chemical expression [18], while a curious increase in ·-
secretase mRNA has been shown in AD hippocampus
and cerebellum, without relationship to the severity of
damage [15]. Yet, modulation of the competition between
·- and ß-secretase activities for the APP substrate has to
be studied in greater details, as in both mice and humans
they are colocalized in cortical neurons, together with
APP [40]. The total Aß deposit, however, largely depends
on Aß clearance and degradation, under the influence of
factors such as ApoE, ·2-macroglobulin or insulin-degrad-
ing enzyme among others [41]. Against the view of Aß as a
major causative factor in AD, several papers have de-
scribed Aß deposits in the brain of old controls without
dementia [42, 43], but others seem to indicate a correla-
tion between Aß deposit and cognitive decline [44, 45].
Further, it has been shown that immunization is able to
clear Aß from the brain of AD patients [46] and that
immunized patients generating antibodies against Aß ex-
hibit a slower cognitive decline [47]. Other authors see the
production of Aß peptide, Aß40 particularly, as a critical
requirement for the viability of central neurons, as the
presence of Aß prevented the toxicity of ß- and Á-secretase
inhibitors on neuronal cell cultures [48]. In addition, APP
processing seems to be involved in synaptic function, with
endogenous Aß participating in a feedback control of neu-
ronal activity [49]. Therefore, in spite of already existing
statin-based peptidomimetic inhibitors of ß-secretase [50,
51], the modulation of endogenous Aß under the control
of secretases should be foreseen with some caution with
regard to possible known and unknown side effects. Our
study shows that the level of BACE protein expression is
not necessarily linked to Aß formation but is increased in
activated astrocytes from AD brains. Further, strong
BACE expression in healthy neurons suggests alternate
unknown functions.
Acknowledgments
We thank Prof. P. Magistretti, Prof. P. Giannakopoulos and Dr.
M. Gaillard for supporting our work.
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
13
0.
60
.4
7.
22
 - 
7/
7/
20
16
 2
:1
7:
44
 P
M
182 Dement Geriatr Cogn Disord 2005;19:171–183 Leuba/Wernli/Vernay/Kraftsik/Mohajeri/
Saini
References
1 Hardy J, Selkoe DJ: The amyloid hypothesis of
Alzheimer’s disease: Progress and problems on
the road to therapeutics. Science 2002;297:
353–356.
2 Vassar R, Bennett BD, Babu-Khan S, Kahn S,
Mendiaz EA, Denis P, Teplow DB, Ross S,
Amarante P, Loeloff R, Luo Y, Fisher S, Fuller
J, Edenson S, Lile J, Jarosinski MA, Biere AL,
Curran E, Burgess T, Louis JC, Collins F, Trea-
nor J, Rogers G, Citron M: ß-Secretase cleav-
age of Alzheimer’s amyloid precursor protein
by the transmembrane aspartic protease
BACE. Science 1999;286:735–741.
3 Bennett BD, Babu-Khan S, Loeloff R, Louis
JC, Curran E, Citron M, Vassar R: Expression
analysis of BACE2 in brain and peripheral tis-
sues. J Biol Chem 2000;275:20647–20651.
4 Cai H, Wang Y, McCarthy D, Wen H, Borchelt
DR, Price DL, Wong PC: BACE1 is the major
beta-secretase for generation of Abeta peptides
by neurons. Nat Neurosci 2001;4:233–234.
5 Murphy T, Yip A, Brayne C, Easton D, Evans
JG, Xuereb J, Cairns N, Esiri MM, Rubin-
sztein DC: The BACE gene: Genomic structure
and candidate gene study in late-onset Alz-
heimer’s disease. Neuroreport 2001;12:631–
634.
6 Nowotny P, Kwon JM, Chakraverty S, Nowot-
ny V, Morris JC, Goate AM: Association stud-
ies using novel polymorphisms in BACE1 and
BACE2. Neuroreport 2001;12:1799–1802.
7 Nicolaou M, Song YQ, Sato CA, Orlacchio A,
Kawarai T, Medeiros H, Liang Y, Sorbi S,
Richard E, Rogaev EI, Moliaka Y, Bruni AC,
Jorge R, Percy M, Duara R, Farrer LA, Georg-
Hyslop P, Rogaeva EA: Mutations in the open
reading frame of the beta-site APP cleaving
enzyme (BACE) locus are not a common cause
of Alzheimer’s disease. Neurogenetics 2001;3:
203–206.
8 Cruts M, Dermaut B, Rademakers R, Roks G,
Van den BM, Munteanu G, Van Duijn CM,
Van Broeckhoven C: Amyloid beta secretase
gene (BACE) is neither mutated in nor associat-
ed with early-onset Alzheimer’s disease. Neu-
rosci Lett 2001;313:105–107.
9 Liu HC, Leu SJ, Chang JG, Sung SM, Hsu WC,
Lee LS, Hu CJ: The association of beta-site
APP cleaving enzyme (BACE) C786G poly-
morphism with Alzheimer’s disease. Brain Res
2003;961:88–91.
10 Gold G, Blouin JL, Herrmann FR, Michon A,
Mulligan R, Duriaux SG, Bouras C, Giannako-
poulos P, Antonarakis SE: Specific BACE1 ge-
notypes provide additional risk for late-onset
Alzheimer disease in APOE varepsilon 4 car-
riers. Am J Med Genet 2003;119B:44–47.
11 Vassar R: Beta-secretase (BACE) as a drug tar-
get for Alzheimer’s disease. Adv Drug Deliv
Rev 2002;54:1589–1602.
12 Roberds SL, Anderson J, Basi G, Bienkowski
MJ, Branstetter DG, Chen KS, Freedman SB,
Frigon NL, Games D, Hu K, Johnson-Wood K,
Kappenman KE, Kawabe TT, Kola I, Kuehn
R, Lee M, Liu W, Motter R, Nichols NF, Power
M, Robertson DW, Schenk D, Schoor M,
Shopp GM, Shuck ME, Sinha S, Svensson KA,
Tatsuno G, Tintrup H, Wijsman J, Wright S,
McConlogue L: BACE knockout mice are
healthy despite lacking the primary beta-secre-
tase activity in brain: Implications for Alz-
heimer’s disease therapeutics. Hum Mol Genet
2001;10:1317–1324.
13 Holsinger RM, McLean CA, Beyreuther K,
Masters CL, Evin G: Increased expression of
the amyloid precursor beta-secretase in Alz-
heimer’s disease. Ann Neurol 2002;51:783–
786.
14 Li R, Lindholm K, Yang LB, Yue X, Citron M,
Yan R, Beach T, Sue L, Sabbagh M, Cai H,
Wong P, Price D, Shen Y: Amyloid beta pep-
tide load is correlated with increased beta-
secretase activity in sporadic Alzheimer’s dis-
ease patients. Proc Natl Acad Sci USA 2004;
101:3632–3637.
15 Gatta LB, Albertini A, Ravid R, Finazzi D:
Levels of beta-secretase BACE and alpha-secre-
tase ADAM10 mRNAs in Alzheimer hippo-
campus. Neuroreport 2002;13:2031–2033.
16 Preece P, Virley DJ, Costandi M, Coombes R,
Moss SJ, Mudge AW, Jazin E, Cairns NJ: Beta-
secretase (BACE) and GSK-3 mRNA levels in
Alzheimer’s disease. Brain Res Mol Brain Res
2003;116:155–158.
17 Fukumoto H, Cheung BS, Hyman BT, Irizarry
MC: Beta-secretase protein and activity are
increased in the neocortex in Alzheimer dis-
ease. Arch Neurol 2002;59:1381–1389.
18 Tyler SJ, Dawbarn D, Wilcock GK, Allen SJ:
Alpha- and beta-secretase: Profound changes in
Alzheimer’s disease. Biochem Biophys Res
Commun 2002;299:373–376.
19 Sun A, Koelsch G, Tang J, Bing G: Localization
of beta-secretase memapsin 2 in the brain of
Alzheimer’s patients and normal aged controls.
Exp Neurol 2002;175:10–22.
20 Gallyas F: Silver staining of Alzheimer’s neuro-
fibrillary changes by means of physical devel-
opment. Acta Morphol Acad Sci Hung 1971;
19:1–8.
21 Kamal A, Almenar-Queralt A, LeBlanc JF, Ro-
berts EA, Goldstein LS: Kinesin-mediated ax-
onal transport of a membrane compartment
containing beta-secretase and presenilin-1 re-
quires APP. Nature 2001;414:643–648.
22 Leuba G, Vernay A, Vu D, Walzer C, Belloir B,
Kraftsik R, Bouras C, Savioz A: Differential
expression of LMO4 protein in Alzheimer’s
disease. Neuropathol Appl Neurobiol 2004;30:
57–69.
23 SAS Institute Inc: SAS/GRAPH Software: Ref-
erence, vol 1, ed 1. Cary, SAS Institute, 1990.
24 Gomez-Isla T, Price JL, McKeel DW, Morris
JC, Growdon JH, Hyman BT: Profound loss of
layer II entorhinal cortex neurons occurs in
very mild Alzheimer’s disease. J Neurosci
1996;16:4491–4500.
25 Fukumoto H, Rosene DL, Moss MB, Raju S,
Hyman BT, Irizarry MC: Beta-secretase activi-
ty increases with aging in human, monkey, and
mouse brain. Am J Pathol 2004;164:719–725.
26 Gomez-Isla T, Hollister R, West H, Mui S,
Growdon JH, Petersen RC, Parisi JE, Hyman
BT: Neuronal loss correlates with but exceeds
neurofibrillary tangles in Alzheimer’s disease.
Ann Neurol 1997;41:17–24.
27 Capell A, Steiner H, Willem M, Kaiser H,
Meyer C, Walter J, Lammich S, Multhaup G,
Haass C: Maturation and pro-peptide cleavage
of beta-secretase. J Biol Chem 2000;275:
30849–30854.
28 Capell A, Meyn L, Fluhrer R, Teplow DB,
Walter J, Haass C: Apical sorting of beta-secre-
tase limits amyloid beta-peptide production. J
Biol Chem 2002;277:5637–5643.
29 Bigl M, Apelt J, Luschekina EA, Lange-Dohna
C, Rossner S, Schliebs R: Expression of beta-
secretase mRNA in transgenic Tg2576 mouse
brain with Alzheimer plaque pathology. Neu-
rosci Lett 2000;292:107–110.
30 Irizarry MC, Locascio JJ, Hyman BT: Beta-site
APP cleaving enzyme mRNA expression in
APP transgenic mice: Anatomical overlap with
transgene expression and static levels with
aging. Am J Pathol 2001;158:173–177.
31 Rossner S, Apelt J, Schliebs R, Perez-Polo JR,
Bigl V: Neuronal and glial beta-secretase
(BACE) protein expression in transgenic
Tg2576 mice with amyloid plaque pathology. J
Neurosci Res 2001;64:437–446.
32 Bodendorf U, Danner S, Fischer F, Stefani M,
Sturchler-Pierrat C, Wiederhold KH, Staufen-
biel M, Paganetti P: Expression of human beta-
secretase in the mouse brain increases the
steady-state level of beta-amyloid. J Neuro-
chem 2002;80:799–806.
33 Ohno M, Sametsky EA, Younkin LH, Oakley
H, Younkin SG, Citron M, Vassar R, Dister-
hoft JF: BACE1 deficiency rescues memory
deficits and cholinergic dysfunction in a mouse
model of Alzheimer’s disease. Neuron 2004;41:
27–33.
34 Hartlage-Rubsamen M, Zeitschel U, Apelt J,
Gartner U, Franke H, Stahl T, Gunther A,
Schliebs R, Penkowa M, Bigl V, Rossner S:
Astrocytic expression of the Alzheimer’s dis-
ease beta-secretase (BACE1) is stimulus-depen-
dent. Glia 2003;41:169–179.
35 Mohajeri MH, Saini KD, Nitsch RM: Trans-
genic BACE expression in mouse neurons ac-
celerates amyloid plaque pathology. J Neural
Transm 2004;111:413–425.
36 Schubert P, Ogata T, Marchini C, Ferroni S:
Glia-related pathomechanisms in Alzheimer’s
disease: A therapeutic target? Mech Ageing
Dev 2001;123:47–57.
37 Tamagno E, Bardini P, Obbili A, Vitali A,
Borghi R, Zaccheo D, Pronzato MA, Danni O,
Smith MA, Perry G, Tabaton M: Oxidative
stress increases expression and activity of
BACE in NT2 neurons. Neurobiol Dis 2002;
10:279–288.
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
13
0.
60
.4
7.
22
 - 
7/
7/
20
16
 2
:1
7:
44
 P
M
BACE Expression in Alzheimer’s Disease Dement Geriatr Cogn Disord 2005;19:171–183 183
38 Neve RL: A new wrestler in the battle between
alpha- and beta-secretases for cleavage of APP.
Trends Neurosci 2003;26:461–463.
39 Li Y, Wang H, Wang S, Quon D, Liu YW, Cor-
dell B: Positive and negative regulation of APP
amyloidogenesis by sumoylation. Proc Natl
Acad Sci USA 2003;100:259–264.
40 Marcinkiewicz M, Seidah NG: Coordinated
expression of beta-amyloid precursor protein
and the putative beta-secretase BACE and al-
pha-secretase ADAM10 in mouse and human
brain. J Neurochem 2000;75:2133–2143.
41 Tanzi RE, Bertram L: New frontiers in Alz-
heimer’s disease genetics. Neuron 2001;32:
181–184.
42 Davis DG, Schmitt FA, Wekstein DR, Markes-
bery WR: Alzheimer neuropathologic altera-
tions in aged cognitively normal subjects. J
Neuropathol Exp Neurol 1999;58:376–388.
43 Snowdon DA: Aging and Alzheimer’s disease:
Lessons from the nun study. Gerontologist
1997;37:150–156.
44 Arends YM, Duyckaerts C, Rozemuller JM,
Eikelenboom P, Hauw J: Microglia, amyloid
and dementia in Alzheimer disease. A correla-
tive study. Neurobiol Aging 2000;21:39–47.
45 Näslund J, Haroutunian V, Mohs R, Davis KL,
Davies P, Greengard P, Buxbaum JD: Correla-
tion between elevated levels of amyloid beta-
peptide in the brain and cognitive decline.
JAMA 2000;283:1571–1577.
46 Nicoll JAR, Wilkinson D, Holmes C, Steart P,
Markham H, Weller RO: Neuropathology of
human Alzheimer disease after immunization
with amyloid-beta peptide: A case report. Nat
Med 2003;9:448–452.
47 Hock C, Konietzko U, Streffer JR, Tracy J, Sig-
norell A, Muller-Tillmanns B, Lemke U, Henke
K, Moritz E, Garcia E, Wollmer MA, Um-
bricht D, de Quervain DJ, Hofmann M, Mad-
dalena A, Papassotiropoulos A, Nitsch RM:
Antibodies against beta-amyloid slow cognitive
decline in Alzheimer’s disease. Neuron 2003;
38:547–554.
48 Plant LD, Boyle JP, Smith IF, Peers C, Pearson
HA: The production of amyloid beta peptide is
a critical requirement for the viability of cen-
tral neurons. J Neurosci 2003;23:5531–5535.
49 Kamenetz F, Tomita T, Hsieh H, Seabrook G,
Borchelt D, Iwatsubo T, Sisodia S, Malinow R:
APP processing and synaptic function. Neuron
2003;37:925–937.
50 Hom RK, Fang LY, Mamo S, Tung JS, Guinn
AC, Walker DE, Davis DL, Gailunas AF,
Thorsett ED, Sinha S, Knops JE, Jewett NE,
Anderson JP, John V: Design and synthesis of
statine-based cell-permeable peptidomimetic
inhibitors of human beta-secretase. J Med
Chem 2003;46:1799–1802.
51 Hu B, Fan KY, Bridges K, Chopra R, Lovering
F, Cole D, Zhou P, Ellingboe J, Jin G, Cowling
R, Bard J: Synthesis and SAR of bis-statine
based peptides as BACE 1 inhibitors. Bioorg
Med Chem Lett 2004;14:3457–3460.
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
13
0.
60
.4
7.
22
 - 
7/
7/
20
16
 2
:1
7:
44
 P
M
